IWEB | IceWEB, Inc. | News Out Today

IceWEB, Inc. IWEB

IWEB has not left our radar for the past several weeks. Still maintaining support above that key .03-level, we wanted to make sure to make it a point of focus this morning as the company announced the arrival of the next generation of IceWEB product. IceBOX v3.0 is an upgrade from version 2 in practically every way. It increases sharing functionality, virus scanning, and boasts a totally redesigned administrative portal, just to name a few of the improvements.

Click through to the full press release below for a complete rundown of the new device enhancements that will now be part of the IceBOX line.

We’re sure that with the addition of this new hardware to IceWEB’s repertoire, the clientele will continue to roll in, as has been the case throughout our coverage of IWEB.

Take a look at the following video explaining what we like about the IWEB chart conditions.

STERLING, Va., Aug 28, 2013 (BUSINESS WIRE) — IceWEB Storage Corporation – (OTCBB:IWEB) today announced the release and immediate availability of IceBOX v3.0.

Based on feedback from customers and partners around the globe, IceWEB has released the latest software version of its IceBOX product, IceBOX v3.0. The software release enhances the Enterprise File Sharing and Synchronization (EFSS) capabilities of IceBOX giving it the most advanced features in its class.

“This release incorporates the feedback and creative input we have been receiving from our IceBOX customers. We are very excited about the increased opportunities available to IceWEB as a result of this major release. Small, medium, and large enterprises all must deal with growing BYOD requirements and IceBOX 3.0, meets those advanced technical and way-of-working demands today,” said Gaurang Mehta, CTO of IceWEB. We will continue to forge the clear and trusted path in the Private Cloud and EFSS markets with IceBOX and other new, exciting solutions to assist our customers with the monumental task of managing their critical enterprise data.” >>> FULL RELEASE


Extended Watchlist:
SWSH, ARTH, ANLY, ASTX, ZLC

 

NVLX | Nuvilex, Inc. | Today’s Focus

We’re adding a new play to our watchlists this morning: Nuvilex, Inc. (NVLX) is a multi-faceted biotech company that has been extremely active in the growth and development of its business over the past month.

NVLX has launched itself into the biotechnology industry with the recently completed full acquisition of Bio Blue Bird AG, which has a proprietary live-cell encapsulation technology which acts as a delivery system for live cells that aid in the treatment of inoperable pancreatic cancer and breast cancer, as well as diabetes.

In fact the technology as a whole can be viewed simply as a platform upon which virtually limitless treatments could be built. Opportunities abound, not only with the follow-though of its own products, but at the prospect of other companies lining up to license NVLX‘s encapsulation technology for use in delivering their own treatments.

The cellulose-based capsules really are a work of genius. At the scale of a pin-head, the microscopic capsules are filled with living cells, either engineered or cultured from natural compounds that are believed to have therapeutic effects, and introduced into the body intravenously or through direct injection. They contain pores which are too small in size to allow for the escape of the cells (or access to immune system cells that might try to destroy the introduced cells), but sufficient in size to facilitate the entry of essential nutrients exit of and waste products and beneficial substances produced by the cells. In this state, the encapsulated samples can survive for long periods of time.

The FDA recently rolled out a new program in which certain approved technologies can receive a  “breakthrough therapy” designation. This designation aids the FDA in helping firms speed up the development of new drugs or therapies that have shown sufficient potential to offer statistically significant improvement over existing treatments for terminal illnesses. If Nuvilex could get approved for this new fast-track program, shares which are now trading in the teens, could soon see much higher value. That’s much of the reason that we’re so excited about the possibilities for NVLX. We think promising Phase II results that have been reported by Nuvilex could lead to Phase III trials under this new program, which would mean big things for this biotech.

For instance, below you can see an image taken from Nuvilex’s website which shows before and after scans of what can only be described as extremely encouraging apparent success in treating a pancreatic tumor.

With one stroke, Nuvilex has catapulted itself into the midst of an exciting prospect- A proprietary, license-able technology that could not only have far reaching implications in business, but how terminal illnesses of all kinds can be treated; something that could benefit all mankind. If it sounds like it has the potential to be a really big deal, that’s because it does. The fact that we’ve stumbled upon this company at this early stage of its new evolution could have some pretty impressive effects as well with regard to the stock.

The addition of this potentially game-changing tech goes well with another arm of NVLX‘s business, Medical Marijuana Sciences, Inc, which is focused on the use of marijuana and its various chemical compounds for the development of treatment for different types of cancer. As many of our followers are well aware, the medical marijuana industry is one that has been of great interest and profit to us over the past year.

Have a look at the NVLX chart below, or click through to the video chart presentation:


 


Recent PRs

>>View All Recent Press


For More Information visit www.nuvilex.com

VLCK Options, OWOO & Extended Watchlist

VCLK Options
Last Monday, we were taking a look at the VCLK Options chain, specifically the $21 09/21 Calls. Following that report we observed a low of 1.10. By week’s end we observed an increase to 1.40 on Friday.

While we have not seen a power-move from VCLK as yet, with almost a month remaining until the expiration date on these contracts, there’s still plenty of time for that to occur. Especially the stock can continue to fill the gap on the chart (as we’ve pointed out below), the 09/21 $21’s could be pushed significantly deeper into the money by the the third week in September rolls around.

So far it has done a good job of posting higher highs and higher lows, and stairstepping its way toward those 50 and 200DMA’s at 23.38 and 24.00 respectively. We’ll be following along as it continues its recovery.


One World Holdings, Inc. OWOO
OWOO is coming off recent 52-week lows, and the company sent out a PR this morning containing some exciting news. They’ve retained the services of Steve Varner for the 3D sculpting of its planned line of celebrity dolls. Designing of two lines of Teenage Mutant Ninja Turtle action figures for Playmate Toys are among Varner’s notable acheivements.

It’s always interesting to observe the behavior of a stock that is coming off of its annual lows, especially one with untraded-upon news, so OWOO is going to be an area of interest for us as we kick off this new trading week.

HOUSTON, Aug 26, 2013 (GLOBE NEWSWIRE via COMTEX) — The One World Doll Project, subsidiary of One World Holdings, Inc. (OTCBB:OWOO) announced that it has partnered with Steve Varner of Varner Studios for all 3D modeling and sculpture work on its upcoming line of celebrity dolls.”When we first partnered with Steve Varner during the development of The Prettie Girls! Dolls, we immediately understood why his name is associated with so many successful toy products including Star Trek, Lara Croft Tomb Raider, The Teenage Mutant Ninja Turtles, McDonald’s Happy Meals and more,” said Joanne Melton, CEO of One World Holdings. “His work has always been of the highest quality and we are thrilled to once again have him as a part of the One World Team,” she added.

For more information on Steve Varner and Varner Studios log onto www.varnerstudios.com


Extended Watchlist:
IWEB,  AVNR, HEB, CGEN, INO, SUNE